Role of trabectedin in the treatment of soft tissue sarcoma.

Details

Ressource 1Download: BIB_F99B330D2A0B.P001.pdf (199.45 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_F99B330D2A0B
Type
Article: article from journal or magazin.
Collection
Publications
Title
Role of trabectedin in the treatment of soft tissue sarcoma.
Journal
Oncotargets and Therapy
Author(s)
Christinat A., Leyvraz S.
ISSN
1178-6930 (Electronic)
ISSN-L
1178-6930
Publication state
Published
Issued date
2009
Peer-reviewed
Oui
Volume
2
Number
9
Pages
105-113
Language
english
Notes
Publication types: Journal Article
WOS Document Type: Review
Abstract
Interest in marine natural products has allowed the discovery of new drugs and trabectedin (ET-743, Yondelis), derived from the marine tunicate Ecteinascidia turbinata, was approved for clinical use in 2007. It binds to the DNA minor groove leading to interferences with the intracellular transcription pathways and DNA-repair proteins. In vitro antitumor activity was demonstrated against various cancer cell lines and soft tissue sarcoma cell lines. In phase I studies tumor responses were observed also in osteosarcomas and different soft tissue sarcoma subtypes. The most common toxicities were myelosuppression and transient elevation of liver function tests, which could be reduced by dexamethasone premedication. The efficacy of trabectedin was established in three phase II studies where it was administered at 1.5 mg/m2 as a 24 h intravenous infusion repeated every three weeks, in previously treated patients. The objective response rate was 3.7%-8.3% and the tumor control rate (which included complete response, partial response and stable disease) was obtained in half of patients for a median overall survival reaching 12 months. In nonpretreated patients the overall response rate was 17%. Twenty-four percent of patients were without progression at six months. The median overall survival was almost 16 months with 72% surviving at one year. Predictive factors of response are being explored to identify patients who are most likely to respond to trabectedin. Combination with other agents are currently studied with promising results. In summary trabectedin is an active new chemotherapeutic agents that has demonstrated its role in the armamentarium of treatments for patients with sarcomas.
Keywords
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 4, Cytarabine/administration & dosage, Dexamethasone/administration & dosage, Disease-Free Survival, Female, Follow-Up Studies, Genetic Heterogeneity, Hemoglobins, Humans, Male, Middle Aged, Multiple Myeloma/drug therapy, Multiple Myeloma/genetics, Multivariate Analysis, Prognosis, Retrospective Studies, Translocation, Genetic, Vincristine/administration & dosage, beta 2-Microglobulin/blood
Pubmed
Web of science
Create date
08/10/2011 18:58
Last modification date
20/08/2019 17:25
Usage data